Atopic Dermatitis News

 
 
  • AAD Oral Eczema Treatments Generate Excitement Impressive phase 2 results raise hope that oral medications will replace injections for atopic dermatitis.
  • AAD Immune Modulation in the Spotlight at AAD 2018 Immunomodulators for inflammatory diseases and cancer will be among the hot topics at the upcoming American Academy of Dermatology meeting.
  • Regeneron CEO Says Fears Over Eylea 'Greatly Exaggerated' Fears of the demise of blockbuster eye drug Eylea (aflibercept) were "greatly exaggerated," Regeneron Pharmaceuticals Inc's chief executive said on Thursday, after the treatment and new eczema drug Dupixent (dupilumab) powered the company's fourth-quarter results.
  • Plain Water Baths as Effective as Bleach Baths for Eczema Bleach baths are no more effective for the treatment of eczema than plain water baths and may cause unpleasant adverse effects such as burning and stinging, a study found.
  • Prescription-Strength Steroid Creams Sold Without Prescription Although the U.S. requires prescriptions for topical steroids with more than a 0.5% concentration, much stronger and potentially harmful steroid creams are not hard to find without a prescription, doctors report.
  • ACAAI Eczema Can Predict Severity of Asthma Hospitalization A family history of asthma and a patient's own history of atopic dermatitis are linked to a more severe hospital experience, according to a study that could influence care decisions.
  • Do Dogs Help Prevent Eczema and Asthma? Animals are a common trigger for eczema and asthma symptoms but two new US studies show dogs may not be the enemy they are often thought to be.
  • ACAAI New Drugs for Atopic Dermatitis Boost Treatment Options For decades there were few options for people with atopic dermatitis, but new choices, with more in the pipeline, have meant a substantial shift in treatment.
  • Dermatology Guideline Authors Take Big Payments From Industry Dermatology clinical practice guideline authors often receive large payments from industry and don't always fully disclose them, researchers report.
  • ACAAI Food Introduction, Chronic Cough Top Allergy Meeting Lineup The challenge of explaining updated guidelines on the introduction of peanut products will be among the topics addressed at the American College of Allergy, Asthma & Immunology (ACAAI) meeting.
  • Alert EU Approves Dupilumab (Dupixent) for Atopic Dermatitis The European Commission has granted marketing authorization to dupilumab for adults with moderate to severe atopic dermatitis, according to a company news release.
  • Lilly/Incyte Pill Beats Placebo in Mid-stage Eczema Trial Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis.
  • Moisturizers Labeled 'Hypoallergenic' May Still Have Toxic Chemicals Many moisturizers promoted as remedies for skin problems like eczema and labeled as `fragrance-free’ or `hypoallergenic’ may still contain chemicals that can cause irritation, a recent U.S. study suggests.
  • EADV Immunotherapies Center Stage at EADV The designated hot topic of this year's European Academy of Dermatology and Venereology (EADV) Congress will have specialists talking about the latest developments in immunotherapies.
  • AAD Atopic Dermatitis in Adults Tough Nut to Crack Only half as many adults as children are affected by atopic dermatitis, but diagnosis is more complicated, and the condition may be underreported in this population.
  • Dermatology Goes to the Dogs, and Human Patients Benefit Animal treatments should inspire new therapies for people with the same conditions, according to presenters at the American Academy of Dermatology 2017 Summer Meeting.
  • Fear Keeps Many Eczema Patients From Using Steroid Creams Many people with eczema may avoid creams and ointments that can help ease symptoms like itching and inflammation because they’re afraid to try topical corticosteroids, a recent study suggests.
  • AAD New Therapies in the Spotlight at AAD Summer Meeting Agents that target interleukin-23 for atopic dermatitis and psoriasis will be among the hot topics presented at the upcoming American Academy of Dermatology (AAD) Summer Meeting.
  • Alert EU Panel Recommends Dupilumab (Dupixent) for Eczema A committee of the European Medicines Agency has recommended marketing authorization for dupilumab (Dupixent) for the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.
  • Large Study Finds No Link Between Eczema, Cardiovascular Disease Atopic dermatitis (AD) is unlikely to be associated with cardiovascular disease, new research shows.